# A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

> **NCT03125746** · PHASE1 · UNKNOWN · sponsor: **Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** LXI-15029
- **DRUG:** LXI-15029+Exemestane

## Key facts

- **NCT ID:** NCT03125746
- **Lead sponsor:** Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-12
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-10-28
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125746, "A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03125746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*